Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6350074 | 0.84 | NRP1 (0.49) | SMN1; SMN2ALDH1A1CDK8 | |
| SCHEMBL10330188 | 0.82 | KDM4E (0.75) | HPGDTSHRHSD17B10KDM4ELMNA | |
| SCHEMBL22904294 | 0.81 | KDM4E (0.55) | HPGDTSHRHSD17B10KDM4ELMNA | |
| SCHEMBL28467589 | 0.81 | ALDH1A1 (0.63) | HPGDTSHRHSD17B10KDM4ELMNA | |
| SCHEMBL22904299 | 0.81 | KDM4E (0.61) | HPGDTSHRHSD17B10KDM4ELMNA | |
| SCHEMBL19018356 | 0.78 | ADORA1 (0.47) | HPGDHSD17B10KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL6342286 | 0.77 | ADORA2A (0.49) | HPGDTSHRHSD17B10KDM4ELMNA | |
| SCHEMBL12679716 | 0.76 | ALDH1A1 (0.52) | HPGDHSD17B10KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6343690 | 0.74 | CD274 (0.42) | HPGDHSD17B10KDM4EHTTSMN1; SMN2 | |
| SCHEMBL6344769 | 0.74 | HSD17B10 (0.46) | HPGDTSHRHSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075352-A1 | 3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-07 | — | — | US | disclosed |
| US-6759410-B1 | CYTOKINE SUPPRESSIVE ANTIINFLAMMATORIES | SMITHLINE BEECHAM CORPORATION | 2004-07-06 | — | — | US | disclosed |
| EP-1248624-A4 | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-1248624-A1 | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001037837-A1 | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075352-A1 | 3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors | MAPKAPK2, MAPKAPK3, CREBBP | HPGD 3167/4885TSHR 3964/4885HSD17B10 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.